The COVID-19 pandemic is well known for increasing telehealth utilization, including remote patient monitoring, but there are still issues with payer coverage policies even a year after the formal end of the public health emergency for COVID.
Osang Healthcare Co. Ltd. is attempting a second listing on the Kosdaq market with an IPO, planned sometime in March, to fund the company’s growth beyond the COVID-19 pandemic.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Perimeter Medical Imaging AI, Trisalus Life Sciences.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aidoc, AMDI, Endologix, Medtronic, Ontrak, Spineart, Wheeler Bio.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AIOmega, Biosense Webster, Femasys, Nevro, Onward Medical, Vapotherm.
The $110 million that Medical Microinstruments Inc. (MMI) recently raised in its series C funding round is testament to its unique position in microsurgery, said Olivier Litzka, a board member at MMI and a partner at Andera Partners. “There are not many companies actually working in that space in robotics,” he told BioWorld.
“The market stinks,” Brian Johnson, a partner and vice chair of Wilmerhale’s corporate practice group, told a U.S. SEC advisory committee Feb. 27, as he painted a gloomy picture of last year’s IPO landscape in the U.S. While the scene was a little brighter than in 2022, a few key indicators could be worrisome, especially the median offering size, which is predictive of the strength of the IPO market, Johnson said
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Cardiai, Centogene, Fire1, Kore, Medical Guardian, Reveal Genomics, Smith & Nephew.
RSS
